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Sir,
In the 5 September issue, Chong et al (2005) reported a
phase II study of 36 patients with metastatic colorectal cancer
treated with a third-line chemotherapy consisting of capecitabine
and mitomycin. The response rate was 15.2%, median failure-free
survival, 5.4 months, and median overall survival, 9.3 months.
No grade 4 toxicity was observed. Although this regimen
seems particularly convenient, the study is questionable by several
aspects. The first point is the imprecision regarding prognostic
factors. In particular, the number of metastatic sites and
several biological factors such as albumin, lactate dehydrogenase,
alkaline phosphatase or carcinoembryonic antigen have not
been detailed. Moreover, there is no mention about the proportion
of patients who have been operated for a primary tumour. Since
these patients benefit from a follow-up, early detection of
metastases can be favoured, leading to the selection of patients
with low tumour burden and finally, to a potential advantage in
terms of therapeutic efficacy and tolerance. Another point is
the first-line therapy which consisted only of 5-fluorouracil (5-FU)
in 33 patients, although only two have had received oxaliplatin.
Moreover, there is no precision regarding the type of 5-FU-based
regimen since a longer progression-free survival has been
clearly demonstrated with the LV5FU2 regimen (bimonthly
combination of high-dose leucovorin and 5-FU bolus plus
continuous infusion) comparatively with the monthly schedule
of low-dose leucovorin and 5-FU (de Gramont et al, 1997).
The authors compare favourably this regimen with results of third-
line treatments in randomised phase III studies, while it
can be admitted that the patients accrued in phase II studies
inevitably are more selected. Another indirect comparison
with cetuximab is questionable since targeted therapies offer their
best activity in combination with chemotherapy (Cunningham
et al, 2004). Conceptually, the probability of response of
mitomycin-C after either oxaliplatin or irinotecan is extremely
low. Moreover, probably oral fluoropyrimidines will replace
5-FU in a vast proportion of the first-line combinations in
advanced diseases, and probably in the adjuvant setting (Twelves
et al, 2005). The efficacy of capecitabine in second-line combina-
tions also might be discussed as illustrated by several recent phase
II studies. No response has been obtained in 22 patients of
the MD Anderson Cancer Center with 5-FU-resistance (Hoff et al,
2004), and in 51 Korean patients refractory to 5-FU and leucovorin
(Lee et al, 2004). The same inefficacy has been observed in 20
Swedish patients who all had received 5-FU, irinotecan and
oxaliplatin (Gubanski et al, 2005). Finally, a poor response
rate of 4.8% has been obtained in 21 Korean patients receiving
mitomycin-C and capecitabine as third-line chemotherapy
after various combinations of 5-FU, irinotecan and oxaliplatin
(Lim et al, 2005). Although toxicity seems moderate, grade 2
stomatitis or grade 2 diarrhoea may deteriorate quality
of life. Moreover, patients participating to therapeutic trials in
university centres are particularly well followed. In this line, the
lack of haemolytic uraemic syndrome should not lead to excessive
self-confidence. In conclusion, this trial does not reflect the current
practice in which irinotecan, oxaliplatin and targeted therapies are
integrated into the two first therapeutic lines. Nevertheless,
mitomycin might eventually be tested in patients ineligible for
reference drugs.
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